An explainer on how insurance coverage works for GLP-1 weight loss drugs and what can affect whether your plan pays.
Recap by typeshit. Full story at GoodRx.
Pharmacist Paige notes the second round of Medicare drug price negotiation starts January 1, 2027, with the semaglutide family on the list.
New generics and steady prices drove the jump in sales value, with Eli Lilly's tirzepatide leading the market.
Bloomberg reports that employer coverage of GLP-1 weight loss drugs is shrinking, leaving fewer US workers with access through their health plans.
UBS says volumes grew about 55% while net prices fell roughly 14%, and points to about 500,000 people joining Lilly's Medicare bridge program in a few months.
She raises concerns about appetite rebounding and weight returning quickly when younger users stop the drugs abruptly.
Vomiting hit 43% on tradipitant versus 58.5% on placebo after a single semaglutide dose. Vanda plans to seek FDA approval for the new use.
Loading…